Rachel Riechelmann, Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, shared an article on X:
“Low dose (LD: ~ 5mg/d) Everolimus similar time to treatment failure to high dose (HD) for pts with Neuroendocrine tumors.
Our retrospective multi center data.
Less dose, less tox, less cost.
We need more dose optimization studies in oncology!”
The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors.
Authors: Rodrigo G. Taboada, et al.
Dr. Rachel Riechelmann is the Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, Sao Paulo, Brazil and also serves as the President of the Brazilian GI Tumors Group (GTG). Prof. Riechelmann is a member of ESMO Scientific Committees (Colorectal and NET), Latin American Society of GI Oncology (SLAGO), the European Society of Neuroendocrine Tumors Advisory Board and Chair – GI LACOG (Latin American Cooperative Oncology Group).
